TFC-003
/ Kukje Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
December 20, 2023
A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
(clinicaltrials.gov)
- P2 | N=60 | Not yet recruiting | Sponsor: Kukje Pharma
New P2 trial • Cardiovascular • Glaucoma • Ophthalmology
1 to 1
Of
1
Go to page
1